Evaluation of the Impact of the UPLUG Device Onto the Infection Rate of Indwelling Central Venous Catheters in Patients Undergoing Chronic Hemodialysis

NCT ID: NCT05670964

Last Updated: 2024-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-16

Study Completion Date

2024-03-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infections are common complications among patients on chronic haemodialysis. Haemodialysis patients with a catheter have a 2- to 3-fold increased risk of hospitalization for infection and death compared with patients with an arteriovenous fistula or graft \[0\].

As it is a major concern for the medical community, this clinical investigation aims at assessing, in real world conditions, the impact of the UPLUG device onto the infection rate of indwelling central venous haemodialysis catheters.

UPLUG-EVIDENCE is an international, multicenter, randomised, open label trial that will evaluate the efficacy of the UPLUG device on the reduction of bacterial infections in patients undergoing chronic haemodialysis with central venous catheter (CVC).

The UPLUG device has been designed to :

1. reduce the haemodialysis catheter openings, hence potentially reducing the infectious risk,
2. improve the lock solution infusion using a positive pressure, limiting the thrombosis risk and associated haemodialysis catheter dysfunction
3. limit the time needed to connect and disconnect the patient, by facilitating how the different steps are operated, and even allowing a connection/disconnection with a single healthcare professional
4. ultimately enhance patient's autonomy with ergonomics \& safe procedures

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 464 end stage renal disease patients undergoing chronic haemodialysis and receiving a new (de novo or replacement) indwelling CVC will be randomly assigned in a 1:1 ratio to perform either standard-of-care dialysis (232) or standard-of-care dialysis associated with the UPLUG device (232).

The UPLUG device consists of 2 parts :

1. the UPLUG Port, a sterile, single use device connected to the distal Luer-Lock connectors of a regular central venous catheter. It may be connected up to 29 days and
2. the UPLUG Disposable, a sterile, single use device indicated for use with the UPLUG Port to perform a chronic haemodialysis therapy. it will be changed at every dialysis session.

Treatment period (16 weeks):

W1:D1 : first connection of the UPLUG Port The patient will be seen by a nurse or an investigator at D29, D57 and D85 for UPLUG port periodical replacement, and at D113 for the definitive withdrawal of the UPLUG port.

Follow-up period (29 days):

A last visit (onsite or call) is planned during the definitive withdrawal of the CVC or no later than 29 days after the end of the treatment period (D113) to assess the safety and well-being of the patient

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Disease, Chronic Hemodialysis Catheter Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multi-centered open labelled two-arm randomized (1:1) superiority trial. One arm will have standard dialysis, the other arm will have dialysis using the UPLUG device
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

UPLUG Arm

Patients will have regular central veinous catheter and UPLUG device for their dialysis sessions.

Group Type EXPERIMENTAL

Connecting valve system

Intervention Type DEVICE

UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter

Central haemodialysis Venous Catheter

Intervention Type DEVICE

Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session

Standard Of Care Arm

Patients will have regular central veinous catheter (standard of care) for their dialysis.

Group Type OTHER

Central haemodialysis Venous Catheter

Intervention Type DEVICE

Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Connecting valve system

UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter

Intervention Type DEVICE

Central haemodialysis Venous Catheter

Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UPLUG Port UPLUG Disposable

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* End-stage renal disease
* Chronic haemodialysis
* indwelling de novo or replacement central veinous catheter

Exclusion Criteria

* Life expectancy \< 1 year
* Renal transplantation already scheduled at inclusion (living donor)
* Current infection of CVC percutaneous or subcutaneous site
* Pregnant or breastfeeding female, or women without a medically significant contraceptive regimen
* Patient with mechanical heart valve
* Patient with an AVF likely to be functional within 1 month
* Strictly more than 3 dialysis sessions a week
* Patient undergoing haemodialysis session \> 4h30
* Participation to another clinical study in the last 30 days period
* Patient unable to give a freely-given, written, informed consent
* Vulnerable participants
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hafedh FESSI, PH

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Dominique JOLY, PUPH

Role: STUDY_DIRECTOR

Assistance Publique - Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Tenon, service de Néphrologie

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP211510

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Assessment of a Wearable Ultrafiltration Device
NCT06832696 NOT_YET_RECRUITING NA
Percutaneous Translumbar Vs Transhepatic Permcath
NCT05666375 NOT_YET_RECRUITING NA